www.finanzen.net bietet Finanznachrichten zum weltweiten BörsengeschehenFinanzenhttps://www.finanzen.netde-definanzen.net GmbHWed, 13 May 2026 16:55:49 +0200https://images.finanzen.net/images/finanzen_net_neu.gifhttps://www.finanzen.netMon, 08 Dec 2025 13:00:00 +0100https://www.finanzen.net/nachricht/aktien/ucb-presents-positive-results-from-gemz-phase-3-study-at-aes-showing-fenfluramine-significantly-reduced-countable-motor-seizure-frequency-in-cdkl5-deficiency-disorder-15342339

• Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF) compared with placebo¹
• Holistic ...
  ]]>https://www.finanzen.net/nachricht/aktien/ucb-presents-positive-results-from-gemz-phase-3-study-at-aes-showing-fenfluramine-significantly-reduced-countable-motor-seizure-frequency-in-cdkl5-deficiency-disorder-15342339Thu, 04 Dec 2025 14:12:00 +0100https://www.finanzen.net/nachricht/aktien/ucb-shares-leading-scientific-research-and-advances-at-american-epilepsy-society-annual-meeting-15335319
  • Phase 3 CDKL5 deficiency disorder (CDD) results: UCB shares 21 scientific abstracts, including the presentation of positive primary efficacy and safety results from a phase 3 study of FINTEPLA^® (fenfluramine)¹ ...
    ]]>https://www.finanzen.net/nachricht/aktien/ucb-shares-leading-scientific-research-and-advances-at-american-epilepsy-society-annual-meeting-15335319